2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Molecular mechanisms of sorafenib action in liver cancer cells.

      Cell Cycle

      Apoptosis, drug effects, genetics, Benzenesulfonates, pharmacology, therapeutic use, Biological Transport, Carcinoma, Hepatocellular, drug therapy, metabolism, Cell Adhesion, Cell Cycle, Cell Line, Tumor, Cell Proliferation, Cell Survival, DNA Repair, DNA Replication, Gene Expression Profiling, Humans, Liver Neoplasms, Mitogen-Activated Protein Kinases, antagonists & inhibitors, Neovascularization, Pathologic, Niacinamide, analogs & derivatives, Phenylurea Compounds, Protein Biosynthesis, Protein Kinase Inhibitors, Pyridines, Signal Transduction, Transcription, Genetic

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib evolves, there is increasing interest in defining the mechanisms underlying its anti-tumor activity. Considering that this specific inhibitor could target unexpected molecules depending on the biologic context, a precise understanding of its mechanism of action could be critical to maximize its treatment efficacy, while minimizing adverse effects. Two human HCC cell lines (HepG2 and Huh7), carrying different biological and genetic characteristics, were used in this study to examine the intracellular events leading to sorafenib-induced HCC cell-growth inhibition. Sorafenib inhibited cell growth in both cell lines in a dose- and time-dependent manner and significantly altered expression levels of 826 and 2011 transcripts in HepG2 and Huh7 cells, respectively. Genes functionally involved in angiogenesis, apoptosis, transcription regulation, signal transduction, protein biosynthesis and modification were predominantly upregulated, while genes implicated in cell cycle control, DNA replication recombination and repair, cell adhesion, metabolism and transport were mainly downregulated upon treatment. However, each sorafenib-treated HCC cell line displayed specificity in the expression and activity of crucial factors involved in hepatocarcinogenesis. The altered expression of some of these genes was confirmed by semiquantitative and quantitative RT-PCR and by western blotting. Many novel genes emerged from our transcriptomics analysis that had not previously been reported to be effected by sorafenib. Further functional analyses may determine whether these genes can serve as potential molecular targets for more effective anti-HCC strategies.

          Related collections

          Author and article information

          Journal
          22801548
          10.4161/cc.21193

          Comments

          Comment on this article